Detalhe da pesquisa
1.
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.
Immunity
; 56(1): 162-179.e6, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630914
2.
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Nature
; 610(7930): 161-172, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171284
3.
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.
Cancer Cell
; 40(10): 1111-1127.e9, 2022 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36113478
4.
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.
Science
; 378(6621): eabl7207, 2022 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36395212
5.
Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction.
Blood
; 113(2): 347-57, 2009 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-18849489
6.
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers.
Cancer Immunol Res
; 8(1): 131-145, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31771984
7.
ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis.
Dev Cell
; 49(3): 409-424.e6, 2019 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31063757
8.
Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
Cancer Immunol Res
; 6(11): 1301-1313, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30131378
9.
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Mol Cancer Ther
; 17(7): 1416-1429, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703842
10.
SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.
Cancer Res
; 76(3): 607-18, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26645564
11.
Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.
Nat Commun
; 6: 6993, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25925867
12.
Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.
Mol Cancer Ther
; 12(8): 1605-15, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23741061
13.
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
J Mol Cell Biol
; 4(4): 207-20, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22467682
14.
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
PLoS One
; 7(7): e40378, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22911700
15.
The p53/p21Cip1/âWaf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.
Pigment Cell Melanoma Res
; 24(1): 219-32, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20955243
16.
Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.
JAMA Dermatol
; 150(8): 901-3, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24919481